The DOI matches its Crossref record; 21 of the 25 references it cites were found in a registry or an index; 3 of the 19 sources its claims cite were checked for support.
Serum levels of androgens and prostate-specific antigen in endometriosis
Open accessAbstract
OBJECTIVE: The aim of the present study was to evaluate the levels of serum androgens and prostate-specific antigen (PSA) levels in patients with endometriosis. MATERIALS AND METHODS: Patients with Stage III/IV (advanced stage) endometriosis were compared to controls with respect to basal serum levels of total testosterone (T), free testosterone (fT), androstenedion (A), dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulphate (DHEA-S), and PSA in the early follicular phase of menstrual cycle for this prospective case control study. RESULTS: Level of T, fT, A, DHEA, and DHEA-S were higher in patients with endometriosis when compared to control subjects, but the difference was not statistically significant. The mean PSA level was 0.0074 +/- 0.0120 ng/ml in patients with endometriosis and 0.0059 +/- 0.0056 ng/ml in control group and there was no statistically significant difference between groups (p = 0.58). CONCLUSION: Serum basal androgens and PSA levels are higher in endometriosis group with respect to control but the differences are not statistically significant.
Overview
CoChat Summary
TL;DR
In a prospective case-control study, serum androgens and prostate-specific antigen (PSA) tended to be higher in women with Stage III/IV endometriosis than in controls, but none of these differences were statistically significant. The authors conclude that basal androgens and PSA are higher in endometriosis without reaching significance.
Key findings
- Total testosterone, free testosterone, androstenedione, DHEA, and DHEA-S were all higher in the endometriosis group than controls, but differences were not statistically significant: T 0.240 ± 0.124 vs 0.215 ± 0.057 ng/mL (p = 0.38); fT 1.674 ± 1.0139 vs 1.237 ± 0.432 ng/mL (p = 0.06); A 1.599 ± 1.279 vs 1.068 ± 0.946 ng/mL (p = 0.12); DHEA 9.439 ± 6.441 vs 7.348 ± 2.119 ng/mL (p = 0.38); DHEA-S 173.6 ± 74.01 vs 169.5 ± 59.9 μmol/mL (p = 0.93).
- Mean PSA was 0.0074 ± 0.0120 ng/mL in endometriosis patients and 0.0059 ± 0.0056 ng/mL in controls, with no statistically significant difference (p = 0.58).
- CA-125 and white blood cell count were significantly higher in the endometriosis group: CA-125 105.7 ± 164 vs 20.96 ± 8.16 U/mL (p < 0.001); WBC 8.444 ± 1.630 vs 6.261 ± 1.870 K/μL (p < 0.001).
- Age, BMI, hematocrit, platelets, estradiol, FSH, LH, and prolactin did not differ significantly between groups.
Methods
- Prospective case-control study conducted January to June 2012 at Dicle University Medical Faculty, Obstetrics and Gynecology Clinic.
- After exclusions, the study included 24 women with laparoscopically/laparotomically and histologically confirmed Stage III/IV endometriosis and 25 controls undergoing surgery for benign gynecologic disorders such as dermoid cyst or tubal ligation.
- Blood was drawn in the early follicular phase (day 2–4) after overnight fasting; PSA, FSH, E2, LH, and DHEA-S were measured by electrochemiluminescence immunoassay, and T, fT, A, and DHEA by radioimmunoassay. Groups were compared using Student’s t test or Mann-Whitney U test, with p < 0.05 considered significant.
Limitations
- The paper states that the small sample size prohibits generalizability of the results.
- The paper states that serum hormone levels may not correlate with the follicular microenvironment.
- Evident from the text: Stage I/II endometriosis patients were excluded because of small sample size, and additional patients were excluded because PSA levels were unavailable, leaving a final sample of 24 endometriosis patients and 25 controls.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 10 Not checked · 13 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased production of androgens may have protective effect such as increasing quality of oocytes.”
What the sources say
- Partly supportedcites [21] [21] Qin Y., Zhao Z., Sun M., Geng L., Che L., Chen Z.J.: 'Association of basal serum testosterone levels with ovarian response and in vitro fertilization outcome'. Reprod. Biol. Endocrinol. , 2011, 20 , 9. - sourceExperimental — accuracy not yet measured
The Background (page not specified) reports that androgen co-treatment could improve oocyte quality in women with diminished ovarian function or premature ovarian failure. It does not establish that increased androgen production itself has this effect, and it notes controversy over whether the treatment protocols improve outcomes. (LLM, conf=0.84)
- Partly supportedcites [22] [22] Barad D., Brill H., Gleicher N.: 'Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function'. J. Assist. Reprod. Genet. , 2007, 24 , 629. Address reprint requests to: M.S. EVSEN, M.D. Dicle University School of Medicine Department of Gynecology and Obstetrics 21280 Diyarbakir (Turkey) e-mail: mevs@gmail.com sourceExperimental — accuracy not yet measured
The Discussion (Barad et al. 2007) does support the general tenor of the claim: it reports that higher baseline testosterone is associated with improved IVF outcomes and higher oocyte numbers retrieved, that androgen-driven FSH-receptor induction 'may then lead to improved follicular survival', and that 'Androgens have been reported to suppress apoptosis [29,30]' — i.e. a protective action on the follicle. However, the paper nowhere attributes increased oocyte QUALITY to androgens; the only quality statement is in the Introduction, where it is a hedged inference about DHEA supplementation from the authors' own prior study ('That study suggested that DHEA may also improve egg and embryo quality [3]'), and the Discussion explicitly calls 'the mechanism of DHEA's action on the ovary' speculative. So the protective-effect half is in the source while the oocyte-quality half, framed as an androgen effect, is not. (LLM, conf=0.72)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean PSA level was 0.0074 ± 0.0120 ng/ml in patients with endometriosis and 0.0059 ± 0.0056 ng/ml in control group and there was no statistically significant difference between groups ( p = 0.58).”
- Also stated in: § Results · p. 2 · plain
“| PSA, ng/mL | 0.0074 ± 0.0120 | 0.0059 ± 0.0056 | 0.58 |”
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · p. 2 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean PSA level was 0.0074 ± 0.0120 ng/ml in patients with endometriosis and 0.0059 ± 0.0056 ng/ml in control group and there was no statistically significant difference between groups ( p = 0.58).”
- Also stated in: § Summary · p. 1 · plain
“Serum basal androgens and PSA levels are higher in endometriosis group with respect to control but the differences are not statistically significant.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Summary · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean PSA level was 0.0074 ± 0.0120 ng/ml in patients with endometriosis and 0.0059 ± 0.0056 ng/ml in control group and there was no statistically significant difference between groups ( p = 0.58).”
- Also stated in: § Results · p. 2 · plain
“| PSA, ng/mL | 0.0074 ± 0.0120 | 0.0059 ± 0.0056 | 0.58 |”
plainn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · p. 2 · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Small sample size of the study prohibits generalizability of the results.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
2 more claims
Create a free account to see all 25 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 12
- The quote only partly states this claim. 4
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Burger, H. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02985-0 · Cited by 771
Androgens stimulate early stages of follicular growth in the primate ovary
Vendola, K. A., Zhou, J., Adesanya, O. O., Weil, S. J., & Bondy, C. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2081 · Cited by 712
Peripheral biomarkers of endometriosis: a systematic review
May, K. E., Conduit-Hulbert, S. A., Villar, J., Kirtley, S., Kennedy, S. H., & Becker, C. M. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq009 · Cited by 418
1 Adrenal and gonadal androgen secretion in normal females
Longcope, C. (1986) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(86)80021-4 · Cited by 332
Danazol for pelvic pain associated with endometriosis
Farquhar, C., Prentice, A., Singla, A. A., & Selak, V. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000068.pub2 · Cited by 210
Barad, D., Brill, H., & Gleicher, N. (2007) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-007-9178-x · Cited by 207
Vendola, K., Zhou, J., Wang, J., & A.Bondy, C. (1999) · Human Reproduction · doi:10.1093/humrep/14.9.2328 · Cited by 186
NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN
Diamandis, E. P., & Yu, H. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70373-6 · Cited by 172
Do androgens have a direct effect on endometrial function? An in vitro study
Tuckerman, E. M., Okon, M. A., Li, T.-C., & Laird, S. M. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00711-1 · Cited by 167
Medical treatment for rectovaginal endometriosis: what is the evidence?
Vercellini, P., Crosignani, P. G., Somigliana, E., Berlanda, N., Barbara, G., & Fedele, L. (2009) · Human Reproduction · doi:10.1093/humrep/dep231 · Cited by 144
Environmental Dioxins and Endometriosis
Rier, S. (2002) · Toxicological Sciences · doi:10.1093/toxsci/70.2.161 · Cited by 119
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue
Yu, H., Diamandis, E. P., Levesque, M., Giai, M., Roagna, R., Ponzone, R., Sismondi, P., Monne, M., & Croce, C. M. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806212 · Cited by 106
The Epidemiology of Pelvic Endometriosis
Houston, D. E., Noller, K. L., Melton, L. J., & Selwyn, B. J. (1988) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-198812000-00005 · Cited by 80
Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess
Melegos, D. N., Yu, H., Ashok, M., Wang, C., Stanczyk, F., & Diamandis, E. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3792 · Cited by 78
Pellicer, A., Valbuena, D., Bauset, C., Albert, C., Bonilla-Musoles, F., Remohı́, J., & Simón, C. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00085-5 · Cited by 73
BUSSEN, S. V. (1992) · Radiology · doi:10.1148/radiology.182.3.642 · Cited by 64
Qin, Y., Zhao, Z., Sun, M., Geng, L., Che, L., & Chen, Z.-J. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-9 · Cited by 63
Is prostate‐specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?
Vural, B., Özkan, S., & Bodur, H. (2007) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2007.00507.x · Cited by 23
Peritoneal fluid volume and sex steroids in the preovulatory period in mild endometriosis
MAHMOOD, T. A., & TEMPLETON, A. (1991) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1991.tb13365.x · Cited by 21
Bahceci, M., Bilge, M., Tuzcu, A., Tuzcu, S., & Bahceci, S. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03351061 · Cited by 13
Research works printed but not linked: 1
- [1][1] Hesla J.S., Rock J.A.: 'Endometriosis'. In: Rock J.A., Jones H.W. (eds). Te Linde's Operative Gynecology . 10th ed. Philadelphia, Lippincott Williams-Wilkins, 2011, 438. -
Cited by
Endometriosis and polycystic ovary syndrome are diametric disorders
Dinsdale, N. L., & Crespi, B. J. (2021) · Evolutionary Applications · doi:10.1111/eva.13244 · Cited by 90
Hager, M., Wenzl, R., Riesenhuber, S., Marschalek, J., Kuessel, L., Mayrhofer, D., Ristl, R., Kurz, C., & Ott, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081210 · Cited by 46
A Low-Testosterone State Associated with Endometrioma Leads to the Apoptosis of Granulosa Cells
Ono, Y. J., Tanabe, A., Nakamura, Y., Yamamoto, H., Hayashi, A., Tanaka, T., Sasaki, H., Hayashi, M., Terai, Y., & Ohmichi, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115618 · Cited by 32
“Several reports have demonstrated that the serum testosterone levels are not decreased in patients with endometriosis [18, 35].”
BackgroundBarrea, L., Verde, L., Annunziata, G., Chedraui, P. A., Petraglia, F., Cucalón, G., Camajani, E., Caprio, M., Gorini, S., Iorio, G. G., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00662-8 · Cited by 30
“Marker of diminished ovarian reserve Testosterone [46, 47] ↓ (generally lower androgen levels observed) Endometriosis patients have significantly lower serum testosterone levels than women without endometriosis (Some studies found no statistically significant difference in total T. highlighting…”
Endogenous Steroid Hormone Concentrations and Risk of Endometriosis in Nurses’ Health Study II
Shafrir, A. L., Mu, F., Eliassen, A. H., Kulkarni, M. T., Terry, K. L., Hankinson, S. E., & Missmer, S. A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac219 · Cited by 5
Metadata
- Authors
- Evsen, M. S., Sak, M. E., Soydinc, H. E., Guven, S., Basaranoglu, S., Hatipoglu, N. K., Evliyaoglu, O., & Gul, T.
- Affiliations
- Dicle University (TR)
- Corresponding author
- Evsen, M.S.
- ORCID
- Venue
- Clinical and Experimental Obstetrics & Gynecology
- Publisher
- IMR Press
- Published
- 2014-08-10
- Volume
- 41
- Issue
- 4
- Pages
- 432-435
- ISSN
- 0390-6663 (ISSN-L)
- OpenAlex
- W2401468627
- Semantic Scholar
- 5c56c0cdcab100b83580167ff94632e85cf77679
- Cited by
- 5
- References
- 25
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2014: 1
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical and Experimental Obstetrics & Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, serum androgens, prostate-specific antigen, total testosterone, free testosterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate, advanced-stage endometriosis, follicular phase
- MeSH terms
- Adult, Androstenedione, Dehydroepiandrosterone, Endometriosis, Female, Follicular Phase, Humans, Prospective Studies, Testosterone, Case-Control Studies, Prostate-Specific Antigen, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.